EcoDrugPlus

40s Ribosomal Protein Sa

Ensembl ID : ENSPLAG00000015950
Gene Symbol: LOC106942607
4 Cross references
514 Possible Orthologues:

40s Ribosomal Protein Sa

Ensembl ID : ENSPLAG00000013936
Gene Symbol: LOC106954823
4 Cross references
514 Possible Orthologues:

5'-Nucleotidase Ecto

Ensembl ID : ENSPLAG00000011412
Gene Symbol: NT5E
4 Cross references
215 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSPLAG00000011256
Gene Symbol: HTR1B
2 Cross references
182 Possible Orthologues:

5-Hydroxytryptamine Receptor 1b

Ensembl ID : ENSPLAG00000003551
Gene Symbol: HTR1B
1 Cross references
181 Possible Orthologues:

5-Hydroxytryptamine Receptor 1f

Ensembl ID : ENSPLAG00000002462
Gene Symbol: HTR1F
4 Cross references
140 Possible Orthologues:

5-Hydroxytryptamine Receptor 2a

Ensembl ID : ENSPLAG00000001422
Gene Symbol: HTR2A
3 Cross references
216 Possible Orthologues:

5-Hydroxytryptamine Receptor 2b

Ensembl ID : ENSPLAG00000019822
Gene Symbol: HTR2B
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 2c-Like

Ensembl ID : ENSPLAG00000022369
Gene Symbol: LOC106954662
3 Cross references
201 Possible Orthologues:

5-Hydroxytryptamine Receptor 3a

Ensembl ID : ENSPLAG00000014758
Gene Symbol: HTR3A
3 Cross references
203 Possible Orthologues:

5-Hydroxytryptamine Receptor 3b

Ensembl ID : ENSPLAG00000014730
Gene Symbol: HTR3B
3 Cross references
174 Possible Orthologues:

5-Hydroxytryptamine Receptor 4

Ensembl ID : ENSPLAG00000022222
Gene Symbol: HTR4
3 Cross references
198 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).